See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no direct evidence suggesting that Cosentyx (secukinumab) has a specific impact on the effectiveness of the Measles, Mumps, and Rubella (MMR) vaccine. However, it is important to note that Cosentyx is an immunosuppressive drug, which can generally affect the immune system's response to vaccines [1].

Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation. By blocking IL-17A, Cosentyx helps reduce inflammation and symptoms in conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [2].

Immunosuppressive drugs like Cosentyx can potentially affect the immune system's ability to respond to vaccines, as the vaccines rely on the immune system to develop immunity [3]. Therefore, it is recommended to consult a healthcare professional before administering any live or attenuated vaccines to individuals taking Cosentyx or other immunosuppressive drugs [4].

In summary, while there is no specific information regarding Cosentyx's impact on MMR vaccine effectiveness, immunosuppressive drugs like Cosentyx can affect the immune system's response to vaccines. It is crucial to consult a healthcare professional for personalized advice regarding vaccinations and immunosuppressive therapy [5].

Sources:
[1] Drugs.com. (2021). Secukinumab. Retrieved from https://www.drugs.com/mtm/secukinumab.html
[2] Mayo Clinic. (2021). Cosentyx (secukinumab). Retrieved from https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20167342
[3] Centers for Disease Control and Prevention. (2021). General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Retrieved from https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
[4] American Academy of Dermatology. (2019). Vaccinations in Patients Receiving Immunosuppressive Agents. Retrieved from https://www.aad.org/member/practice/clinical/guidelines/immunosuppressive-agents/vaccinations
[5] DrugPatentWatch. (2021). Cosentyx (secukinumab). Retrieved from https://www.drugpatentwatch.com/drugs/cosentyx